VIE/MRNA (VIE/MRNA)

Vienna Stock Exchange: VIE/MRNA · EUR

€196

+2.50 (+1.3%)· Recorded snapshot

Market cap	77.7B
Revenue (ttm)	2B
Net income (ttm)	-2.8B
EPS (ttm)	-€7.19
Volume	345

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2B
Net income (ttm): -2.8B
EPS (ttm): -€7.19
Market cap: 77.7B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-39

P25 n/aP50 n/aP75 n/a

ROIC-76

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All VIE/MRNA indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	United States
Country code	AT
Earnings date	2026-11-06
Employees	4,700
Employees change	-1,100
Employees growth	-18.97%
Enterprise value	EUR 72.7B
Exchange	Vienna Stock Exchange
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	2010
Industry	Biotechnology
Is primary listing	No
ISIN number	US60770K1079
Last earnings date	2026-07-31
Last refreshed	2026-10-29
Market cap	EUR 77.7B
Next earnings date	2026-11-06
Price	EUR 195.86
Price currency	EUR
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-29
Symbol	vie/MRNA
Website	https://www.modernatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-3.67%
EV/Sales	35.85x
FCF / EV yield	-1.52%
FCF yield	-1.42%
P/B ratio	12.96x
P/S ratio	39.34x
Price / tangible book value	13.28x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-109.34%
EBITDA margin	-98.52%
Gross margin	-66.02%
Operating margin	-109.34%
Pretax margin	-138.55%
Profit margin	-141.43%
Profit per employee	EUR -586,823
Revenue per employee	EUR 414,929
ROA	-13.26%
ROA (5Y)	6.72%
ROCE	-28.91%
ROE	-39%
ROE (5Y)	22.02%
ROIC	-75.99%
ROIC (5Y)	40.43%
SBC / revenue	20.74%
Tax / revenue	2.87%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	2
Net income growth quarters	1
Net income growth years	2
Revenue growth	-27.62%
Revenue growth (Q)	2.11%
Revenue growth (QoQ)	-62.72%
Revenue growth 3Y	-40.64%
Revenue growth 5Y	-20.51%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR -149.7M
Depreciation and amortization	EUR 216.3M
EBIT	EUR -2.1B
EBITDA	EUR -1.9B
EPS	EUR -7.19
Financing cash flow	EUR 534.8M
Free cash flow	EUR -1.1B
Free cash flow minus SBC	EUR -1.5B
Gross profit	EUR -1.3B
Income taxes	EUR 56M
Investing cash flow	EUR 792.1M
Net borrowing	EUR 518.7M
Net cash flow	EUR 387.8M
Net income	EUR -2.8B
Operating cash flow minus SBC	EUR -1.3B
Operating income	EUR -2.1B
Revenue	EUR 2B
Stock-based compensation	EUR 404.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.62
Book value per share	EUR 14.83
Debt / equity	0.19
Goodwill	EUR 46.7M
Interest coverage	-58
Long-term assets	EUR 4.4B
Long-term liabilities	EUR 1.4B
Net cash (debt)	EUR 4.9B
Net cash / market cap	6.42%
Net cash growth	-16.87%
Net debt / equity	-0.83
Piotroski F-Score	2
Property, plant and equipment	EUR 2.5B
Shareholders' equity	EUR 5.9B
Tangible book value	EUR 5.8B
Tangible book value per share	EUR 14.48
Total assets	EUR 9.6B
Total cash	EUR 4.5B
Total debt	EUR 1.1B
Total liabilities	EUR 3.7B

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.19
Current assets	EUR 5.2B
Current liabilities	EUR 2.3B
Current ratio	2.29
Inventory turnover	14.23
Net working capital	EUR -1.6B
Quick ratio	2.07
Working capital	EUR 2.9B
Working capital turnover	0.49

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.94%
Shareholder yield	-1.94%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	EUR 85.26
1D price change	1.29%
1M price change	12.68%
1M total return	12.68%
1W price change	-12.41%
1W total return	-12.41%
1Y price change	758.62%
1Y return CAGR	759.88%
1Y total return	758.62%
20-day SMA	EUR 189.63
200-day SMA	EUR 74.32
3M price change	304.05%
3M total return	304.05%
3Y price change	177.34%
3Y return CAGR	40.49%
3Y total return	177.34%
50-day SMA	EUR 157.21
50-day SMA vs 200-day SMA	50over200
52-week high	EUR 220.90
52-week high date	2026-10-21
52-week low	EUR 19.48
52-week low date	2025-11-21
5Y price change	-34.28%
5Y return CAGR	-8.05%
5Y total return	-34.28%
6M price change	374.21%
6M total return	374.21%
All-time high	EUR 423.85
All-time high date	2021-08-10
All-time low	EUR 19.48
All-time low date	2025-11-21
Average true range (ATR)	EUR 12.86
Average volume	215.7
Change from 52-week high	-11.34%
Change from 52-week low	905.34%
Change from all-time high	-54.38%
Change from all-time low	892.51%
Change from open	1.26%
Day's gap	0.03%
Dollar volume	EUR 67,572
High price	EUR 199.76
Low price	EUR 193.42
Monthly RSI	78.65
Open price	EUR 193.42
Position in 52-week range	38.49%
Previous close	EUR 193.36
Price vs 150-day SMA	126.78%
Price vs 20-day SMA	1.97%
Price vs 200-day SMA	160.19%
Price vs 50-day SMA	23%
Relative volume	1.6
RSI	56.19
Sharpe ratio	2
Sharpe ratio (3Y)	0.68
Sharpe ratio (5Y)	0.31
Sortino ratio	6.31
Sortino ratio (3Y)	1.55
Sortino ratio (5Y)	0.68
Volume	345
Weekly RSI	82.15
YTD price change	628.15%
YTD total return	628.15%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	372M
Shares change (QoQ)	0.76%
Shares change (YoY)	1.94%
Shares held by insiders	6.74%
Shares held by institutions	80.51%
Short ratio	1.6 days

Deeper analysis on VIE/MRNA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this VIE/MRNA report

Is a complete VIE/MRNA research report available?

No complete published report is available for vie/MRNA (VIE/MRNA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

VIE/MRNA (VIE/MRNA)

Price

Financial snapshot

Fair-value bridge

Latest news · VIE/MRNA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All VIE/MRNA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on VIE/MRNA

Frequently asked questions